Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05621096 · ClinicalTrials.gov registry record · Phase 1
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
A Phase 1 study of Follicular Lymphoma and High Grade B-Cell Lymphoma, sponsored by University of Nebraska.
- Active
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT05621096 is a Phase 1 study of Follicular Lymphoma and High Grade B-Cell Lymphoma that is active but no longer recruiting, run by University of Nebraska. The registered enrollment target is 33 participants, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05621096, a Phase 1 study of Follicular Lymphoma and High Grade B-Cell Lymphoma, is active but no longer recruiting, sponsored by University of Nebraska.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about treatment for people with B-cell lymphoma that did not respond to treatment or that has gotten worse after treatment. The aim of this trial is to answer the following questions: * If it is realistic to give people radiation treatment before they receive a chimeric antigen receptor (CAR) T-cell treatment for their cancer * If it is safe to give people radiation treatment before they receive a CAR T-cell treatment for their cancer
Conditions Studied
Interventions
- BIOLOGICAL Liso-cel
- RADIATION Bridging radiation therapy
- RADIATION Post-infusion radiation
Study Locations (1)
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-03-21 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05621096
The ClinicalTrials.gov registry entry for NCT05621096 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (76% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Liso-cel is the first listed.
NCT05621096 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT05621096 about?
NCT05621096 is a clinical study titled "Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma". The goal of this clinical trial is to learn about treatment for people with B-cell lymphoma that did not respond to treatment or that has gotten worse after treatment. The aim of this trial is to answer the following questions: * If it is realistic to give people radiation treatment before they rec...
What is the current status of trial NCT05621096?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2023-03-21. Estimated completion is 2027-09.
What conditions does trial NCT05621096 study?
This clinical trial studies the following conditions: Follicular Lymphoma, High Grade B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT05621096?
The interventions under investigation include: Liso-cel (BIOLOGICAL), Bridging radiation therapy (RADIATION), Post-infusion radiation (RADIATION).
Who is sponsoring clinical trial NCT05621096?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05621096 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.